30 July 2013
Domain Associates and Rusnano, the state-funded $10 billion Russian fund, made their fifth investment under a 2012 investment partnership in Domain portfolio company ReVision Optics Inc. (Lake Forest, Calif.).
The ophthalmic device company raised $55 million in an undisclosed equity round from existing investors Canaan Partners; ProQuest Investments; InterWest Partner; and Domain, as well as new investors Rusnano and the Johnson & Johnson Development Corp. venture arm of Johnson & Johnson (NYSE:JNJ).
ReVision's Raindrop microscopic hydrogel inlay is in Phase III testing to treat presbyopia, the gradual loss of the eyes' ability to focus actively on nearby objects. The company markets the product in Europe and some Asian countries. As part of the financing, ReVision partnered with NovaMedica (Moscow, Russia), a JV between Domain and Rusnano, to commercialize Raindrop in the Commonwealth of Independent States (CIS).
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024